ALB and neoplasm: Of note, our approach should allow three levels of treatment selectivity owing to: (i) the use of HSA as endogenous carrier of nanoparticles; (ii) the use of PTX prodrugs capable of preferentially releasing the drug within the tumor; (iii) the intrinsic selective action of PDT.